Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adequate complete blood counts, liver and renal function~* Female subjects must be of non-childbearing potential; e.g. post-menopausal or pre-menopausal with surgical sterilization~* Male subjects agree to use appropriate contraception~* Willing to provide written informed consent and willing to comply with study requirements.~* Non-smokers and non-nicotine users for at least 90 days before screening~* On stable statin co-medication \[for designated multiple dose cohorts only\]~Exclusion Criteria:~* Any uncontrolled or serious disease, or any medical or surgical condition, that may interfere with participation in the clinical study and/or put the subject at significant risk~* Received an investigational agent within 90 days before the first dose of study drug or are in follow-up of another clinical study~* History of multiple drug allergies or intolerance to subcutaneous injection~* Received any medication or nutraceutical to alter serum lipids within 30 days before screening (non-statin cohorts only)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- ALN-PCSSC (Type: ACTIVE_COMPARATOR): None
- Sterile Normal Saline (0.9% NaCl) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).